Catalyze NHLBI Funding Opportunities


WE-REACH is a qualified accelerator partner for the National Heart Lung and Blood Institute’s (NHLBI) new Catalyze Program.

The NHLBI Catalyze Program provides a comprehensive suite of support and services to facilitate the translation of basic scientific discoveries into viable therapeutics, devices, and diagnostics ready for human testing.

The program has three main goals:

  • To drive development of new heart, lung, blood, and sleep (HLBS)-related therapies and cures —including drugs, devices, diagnostics, and biologics—by supporting early product definition studies and safety testing
  • To support development of novel, enabling platform technologies that catalyze next-generation predictive, diagnostic and therapeutic products. These products will specifically address HLBS-related disorders and diseases
  • To train a diverse, globally competitive biomedical workforce that is well-versed in scientific research, technology development, and entrepreneurship

Catalyze Flowchart

As an accelerator partner, WE-REACH can partner with projects to progress from the initial R61 phase into the R33 phase or to begin directly in the R33 phase.

By partnering with teams, WE-REACH provides milestone-driven project management and access to experienced entrepreneurs and scientists to accelerate development and maximize medical impact.

Catalyze currently has 5 funding opportunities.

Applications for non-AIDS related applications are due on March 9, 2021 (Spring) and July 9, 2021 (Summer). AIDS-related applications are due on May 11, 2021 (Spring) and August 11, 2021 (Summer). The earliest start date for both AIDS and non-AIDS related funding opportunities is December 2021 for the Spring cycle and April 2022 for the Summer cycle.

For more information see the Catalyst NHLBI website here along with the Frequently Asked Questions here.